Skip to main content

Site notifications

LUTATHERA Novartis Pharmaceuticals Australia Pty Ltd

Product name
LUTATHERA
Accepted date
Sep-2024
Active ingredients
lutetium (177Lu) oxodotreotide
Proposed indication
Treatment of somatostatin receptor-positive
gastroenteropancreatic neuroendocrine tumours in adults.
Application type
A (new medicine)
Publication date
Sep-2024

Help us improve the Therapeutic Goods Administration site